Search

AstraZeneca PLC

Cerrado

SectorSalud

11,132 -1.83

Resumen

Variación precio

24h

Actual

Mínimo

11068

Máximo

11132

Métricas clave

By Trading Economics

Ingresos

1.3B

2.9B

Ventas

-1.3B

14B

P/B

Media del Sector

29.321

40.048

Rentabilidad por dividendo

2.87

Margen de beneficio

21.46

Empleados

94,300

EBITDA

648M

5.1B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+20.74% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.87%

2.45%

Fecha Próximo Dividendo

8 sept 2025

Próxima Fecha de Ex Dividendo

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-15B

167B

Apertura anterior

11133.83

Cierre anterior

11132

Noticias sobre sentimiento de mercado

By Acuity

64%

36%

327 / 375 Clasificación en Healthcare

AstraZeneca PLC Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

29 jul 2025, 08:08 UTC

Ganancias

AstraZeneca Books Record Quarterly Revenue as U.S, Oncology Boosts Growth -- Update

29 jul 2025, 06:46 UTC

Ganancias

AstraZeneca Books Record Quarterly Revenue as Oncology Boosts Growth

1 ago 2025, 11:10 UTC

Acciones populares

Global Stocks to Watch: Novo Nordisk, AXA, Daimler Truck -- WSJ

29 jul 2025, 11:02 UTC

Ganancias

AstraZeneca 2Q Adj EPS $2.17 >AZN.LN

29 jul 2025, 11:02 UTC

Ganancias

AstraZeneca 2Q EPS $1.58 >AZN.LN

29 jul 2025, 11:01 UTC

Ganancias

AstraZeneca 2Q Rev $14.5B >AZN.LN

29 jul 2025, 11:00 UTC

Ganancias

AstraZeneca Results: H1 and Q2 2025

29 jul 2025, 08:00 UTC

Charlas de Mercado
Ganancias

AstraZeneca Holding Back on a Guidance Upgrade Disappoints -- Market Talk

29 jul 2025, 07:53 UTC

Charlas de Mercado
Ganancias

AstraZeneca Continues to Deliver Under U.S. Tariff Threat -- Market Talk

29 jul 2025, 07:26 UTC

Charlas de Mercado
Ganancias

AstraZeneca Shares Look Undervalued -- Market Talk

29 jul 2025, 06:03 UTC

Ganancias

Analysts Saw AstraZeneca 2Q Total Revenue at $14.15B

29 jul 2025, 06:03 UTC

Ganancias

AstraZeneca 2Q Total Revenue $14.46B

29 jul 2025, 06:03 UTC

Ganancias

Analysts Saw AstraZeneca 2Q Core EPS at $2.16

29 jul 2025, 06:03 UTC

Ganancias

AstraZeneca 2Q Core EPS $2.17

29 jul 2025, 06:02 UTC

Ganancias

AstraZeneca Sees Core EPS Increasing by a Low Double-Digit Percentage

29 jul 2025, 06:02 UTC

Ganancias

AstraZeneca Sees Total Revenue Increasing by a High Single-Digit Percentage

29 jul 2025, 06:02 UTC

Ganancias

AstraZeneca Backs 2025 View

29 jul 2025, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q Rev $14.46B

29 jul 2025, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q Adj EPS $2.17

29 jul 2025, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q Pretax Pft $3.13B

29 jul 2025, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q Net Pft $2.45B

29 jul 2025, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q Oper Pft $3.51B

29 jul 2025, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q EPS $1.57

28 jul 2025, 10:51 UTC

Charlas de Mercado

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

22 jul 2025, 10:19 UTC

Charlas de Mercado

AstraZeneca's Big U.S. Spending Plans Could Put NY Listing on the Table -- Market Talk

22 jul 2025, 09:34 UTC

Acciones populares

Stocks to Watch Tuesday: Coca-Cola, GM, AstraZeneca, NXP -- WSJ

9 jul 2025, 10:59 UTC

Charlas de Mercado

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

9 jul 2025, 09:17 UTC

Acciones populares

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

28 may 2025, 18:09 UTC

Ganancias

Heart Disease Could Be a Goner When These New -2-

28 may 2025, 18:09 UTC

Ganancias

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

AstraZeneca PLC Esperado

Precio Objetivo

By TipRanks

20.74% repunte

Estimación a 12 meses

Media 13,406.92 GBX  20.74%

Máximo 16,500 GBX

Mínimo 10,900 GBX

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AstraZeneca PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

9

Comprar

3

Mantener

0

Vender

Sentimiento

By Acuity

327 / 375 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.